

Director/PDMR Shareholding

July 26, 2018

Released: July 26, 2018 17:33

RNS Number: 9375V

MaxCyte, Inc. 26 July 2018

MaxCyte, Inc. ("MaxCyte" or the "Company")

Person Closely Associated Dealing

Maryland, USA, 26 July 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that Karin Johnston, wife of John Johnston, Non-Executive Director of the Company, has bought 11,500 shares of common stock of 0.1 pence each in the capital of the Company ("Common Stock") at a price of 240 pence per Common Stock.

Following this purchase, John Johnston has a beneficial interest of 86,500 Common Stock, representing 0.2% of the issued share capital of the Company and a further 64,800 options over Common Stock.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Karin Johnston	
2	Reason for the notification		
a)	Position/status	Person closely associated	
b)	Initial notification/Amendment	Initial notification	

3	Details of the issuer, auctioneer or auction mo		participant, auction platform,	
a)	Name	MaxCyte, Inc.		
b)	LEI	54930053YHXULRFCU991		
4		the transaction(s): section to be repeated for (i) each type of instrument; (ii) of transaction; (iii) each date; and (iv) each place where transactions have ucted		
a)	Description of the financial instrument, type of instrument	Purchase of Common Stock		
b)	Identification Code	US57777K1060		
c)	Nature of the transaction	Purchase of Common Stock by a person closely associated		
d)	Price(s) and volume(s)	Price(s)	Volume(s)	
		240.00 pence	11,500	
e)	Aggregated information	N/A (Single Transaction) 11,500 240.00		
	- Aggregated volume			
	- Price			
f)	Date of the transaction	26 July 2018		
g)	Place of the transaction	London Stock Exchange, AIM Market		

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer

+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Emma Earl, Freddy Crossley, Ryan McCarthy (Corporate Finance) +44 (0) 20 7886 2500 James Stearns (Corporate Broking)

Financial PR Adviser

Consilium Strategic Communications

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit www.maxcyte.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAKXKADAPEFF